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Abstract 
Introduction: The study aimed to investigate whether the preparation, storage, and use of autologous serum in insulin syringes is 
microbiologically safe. 
Methodology: Blood samples (10 mL) were obtained from 10 volunteers. After centrifugation, the supernatant serum was removed and 
distributed in 5 sterile insulin syringes for each sample; syringes were numbered 0 to 4 and labelled with the subject’s details. Syringes were 
immediately transported to the microbiology laboratory and stored in a refrigerator at +4°C. The “0” labelled syringes were separated from 
the others and 100 µl of serum from each syringe was immediately seeded on chocolate and Sabouraud agar plates, which were incubated 
aerobically at 37°C for 96 hours to detect any bacterial and/or fungal contamination. In the next 4 days, the same procedure was repeated for 
the remaining syringes: on day 1, the “1” labelled syringes were analyzed; on day 2, the “2” labelled ones, and so on. In a second experiment, 
blood samples were obtained from 5 different volunteers. The same procedure as above was followed, but each syringe was used for repeated 
cultures at 2-hour intervals, for a total of 12 cultures/day. The needle was removed and replaced for each inoculation and the syringes were 
stored in the refrigerator after use. 
Results: Under these experimental conditions, none of the cultures showed microbial growth. 
Conclusions: Results suggest that, under the protocol described, preparation, storage and use of undiluted autologous serum in insulin 
syringes is inexpensive, fast, and microbiologically safe. This is of great importance for low-income countries. 
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Introduction 
Eye-drops made from autologous serum (AS) have 
been reported to be effective in the management of 
ocular surface disorders, such as persistent epithelial 
defects and severe dry eye syndrome, and after ocular 
surface reconstruction [1-6]. Their beneficial effect on 
the damaged ocular surface is related to the supply of a 
series of epitheliotrophic factors [1]. Since AS eye-
drops have a high protein content, there is some risk of 
microbial colonisation. Added preservatives are 
usually avoided because of their toxicity, which can 
negatively affect the epitheliotrophic properties of 
serum. Furthermore, the addition of bacteriostatic 
agents may not be necessary, because the serum itself 
has several anti-microbial agents, including lysozyme, 
complement, and immunoglobulins. The published 
protocols for the preparation and storage of AS eye-
drops are incomplete or vary significantly [1-9]. With 
the increasing use of AS eye-drops, it is important to 
have information on their sterility, as ocular surface 
infections during AS use have been reported [2,3]. 
Furthermore, the availability of a cheap and rapid 
method would be of great importance for low-income 
countries, where ocular surface disorders needing 
treatment with AS are common. 
As far as we know, no report assessing insulin 
syringe use for AS eye-drop preparation has been 
previously published. The purpose of this study was to 
investigate whether the preparation, storage, and use 
of AS in insulin syringes is microbiologically safe. 
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Methodology 
A blood sample was obtained from 10 healthy 
volunteers (5 males and 5 females) during the same 
morning. Under aseptic conditions, venesection was 
performed at the antecubital fossa and 10 mL of whole 
blood were collected in sterile vacutainer tubes 
without additive. The blood was left to clot at 4°C for 
2 hours before centrifuging at 302 g for 10 minutes. 
The supernatant serum was removed in a laminar flow 
cabinet and distributed in five sterile insulin syringes 
(0.5 ml/syringe, ~12-13 drops) for each sample, 
numbered 0 to 4 and labelled with the subject’s details. 
The syringes were then re-capped with a new, sterile 
needle with its cap. Each batch of syringes was put in 
a separate thermal container at +4°C, immediately 
transported to the microbiology laboratory and stored 
in a refrigerator at +4°C, while the “0” labelled 
syringes were separated from the others. After the 
needle was removed, 100 µl of serum from the “0” 
labelled syringes was immediately seeded on 
chocolate agar with no antibiotics and Sabouraud agar 
with chloramphenicol and gentamicin; the remaining 
serum was discarded. The plates were incubated 
aerobically at 37°C for 96 hours to detect any bacterial 
and/or fungal contamination. In the next four days, the 
same procedure was repeated for the remaining 
syringes: the “1” labelled syringes were analyzed on 
day 1; the “2” labelled syringes on day 2, and so on.  
In a second experiment, blood samples were 
obtained from five healthy volunteers. The same 
procedure as above was followed, but each syringe 
was used for repeated cultures at 2-hour intervals on 
the same day, for a total of 12 cultures/day for each 
syringe. In the next four days, the same procedure was 
repeated for the remaining syringes. The needle was 
removed and replaced for each inoculation and the 
syringes were stored in the refrigerator after use, until 
they were finally discarded after the last instillation. 
In both experiments, one Staphylococcus aureus 
and one Pseudomonas aeruginosa reference strain 
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obtained from the American Type Culture Collection 
(ATCC 43300 and ATCC 27853, respectively; ATCC, 
Manassas, VA) and one clinical isolate of Candida 
albicans were used as positive controls. Sterile 
phosphate buffered saline solution (PBSS) was used as 
negative control. 0.5% McFarland standard 
suspensions [10
8
 colony-forming units (CFU)/mL] of 
S. aureus, P. aeruginosa, and C. albicans were 
prepared. Twenty μl of each suspension and 20 μl of 
sterile PBS were plated on chocolate agar and 
Sabouraud agar with antibiotics concurrently with the 
serum cultures.  
Approval from the Ethics Committee/Institutional 
Review Board of the Department of Surgical, 
Microsurgical, and Medical Sciences, University of 
Sassari, Sassari, Italy, was obtained and the study was 
conducted in complete accord with the principles of 
the Declaration of Helsinki. Each participant received 
detailed information and provided written informed 
consent before inclusion. 
 
Results 
In the first assay, 50 serum syringes were prepared 
(5 syringes from each blood sample). A total of 100 
cultures (50 on chocolate agar and 50 on Sabouraud 
agar with chloramphenicol and gentamicin) in 5 days 
(20 cultures/per day) were performed. Under the 
conditions used in this experiment, none of the 
chocolate and Sabouraud agar plates seeded with 
undiluted serum showed any microbial growth after 
aerobic incubation at 37°C for 96 hours. 
In the second experiment, 30 serum syringes were 
prepared (6 syringes from each blood sample). For 
each blood sample, one syringe per day was used. 
Repeated undiluted serum cultures were performed at 
2-hour intervals, for a total of 12 cultures/day per 
syringe (6 on chocolate agar and 6 on Sabouraud agar 
with antibiotics) for a total of five days. On the whole, 
300 cultures in 5 days (60 cultures per day) were 
obtained. In this case too, all cultures yielded no 
microbial growth (Table 1). 
In both experiments, all the chocolate agar plates 
seeded with S. aureus and P. aeruginosa and all the 
Sabouraud agar plates seeded with C. albicans 
(positive controls) showed microbial growth, whereas 
no growth was observed in the corresponding plates 
inoculated with sterile PBSS (negative control).  
 
Discussion 
AS eye-drops have been used for the treatment of 
ocular surface disorders, such as Sjögren syndrome- 
and graft vs host disease (GvHD)-related 
keratoconjunctivitis sicca, superior limbal 
keratoconjunctivitis, recurrent erosion syndrome, 
persistent epithelial defects resulting from rheumatoid 
arthritis, neurotrophic keratopathy, or dry eye, as well 
as an adjunctive treatment in ocular surface 
reconstruction following Stevens-Johnson syndrome, 
toxic epidermal necrolysis (TEN), and cicatricial 
pemphigoid [1-6]. 
Serum is the fluid component of the full blood that 
remains after clotting. It contains a large variety of 
growth factors, including epidermal growth factor 
(EGF) and transforming growth factor-beta (TGF-
beta), immunoglobulins, and vitamins, some in higher 
concentrations than in natural tears [1]. The growth 
and migration-promoting effects of serum on human 
corneal epithelial cells are well known and its 
therapeutic effect on the damaged ocular surface is 
thought to be related to the supply of a series of 
epitheliotrophic factors [4-10]. In the ophthalmic 
literature, there are a number of protocols for 
preparation and storage of AS eye-drops, which vary 
considerably from each other [1-9]. While it is obvious 
that serum from various patients will not be identical, 
other factors, including centrifugation and addition of 
diluents and/or preservatives or antibiotics, may 
significantly affect its biochemical, immunological, 
and epitheliotrophic properties, thus reducing its 
beneficial effect on the damaged ocular surface [1]. 
The frequency of administration of AS eye-drops 
has not been standardized so far. In different studies, it 
ranged from as often as 1/4 hourly to 3 times daily [1-
6]. Serum is usually instilled as a preservative-free, 
autologous product, thus lacking antigenicity. The 
addition of preservatives or antibiotics is usually 
avoided, because they can negatively affect some of 
the beneficial effects of AS and worsen the ocular 
surface damage. On the other hand, even though the 
serum itself has some anti-microbial properties due to 
the presence of lysozyme, complement, and 
immunoglobulins, the lack of added preservatives or 
antibiotics may expose it to the risk of microbial 
contamination during preparation, storage, and use. 
Repeated administration of preservative-free AS eye-
drops from the same container with refrigerator 
storage between applications may increase the risk of 
microbial contamination, especially if the container is 
used for a prolonged period of time. As a result, some 
authors strongly recommend to avoid using the same 
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container for more than a week or, preferably, 
replacing it every day [1,7,11,12].  
In a previous study, Sauer et al. assessed the 
contamination of AS eye-drops containers in a hospital 
setting [8]. These authors failed to find any 
contamination in the samples analyzed on the day of 
preparation and in the eye drops tested four days later; 
however, they found that three (7.5%) out of 40 
containers were contaminated with Staphylococcus 
epidermidis after a week’s use. Similarly, Garcia 
Jimenez et al. [13] reported no contamination of AS 
containers tested on the day of preparation, but 
disclosed contamination rates of approximately 30% in 
containers from home-treated patients after five days 
of use.
 
In another hospital-based survey, Lagnado et 
al. [7] observed bacterial growth in 13 (8.8%) out of 
134 cultures from AS samples, with S. epidermidis as 
the most common isolate (84.6%). Furthermore, in a 
study by Leite et al. [14], microbiological analysis 
revealed that six out of 11 AS samples were 
contaminated after 30 days of use, with Klebsiella 
pneumoniae and Streptococcus viridans as the 
predominant isolates. More recently, López-García 
and García-Lozano [9] reported that only one (2.1%) 
out of 48 AS containers with an adapted sterilizing 
filter (ABAK, Théa, Clermont-Ferrand, France) 
resulted contaminated with S. epidermidis after 1 
month of treatment, whereas the contamination rate 
among 128 conventional AS containers was 28.9% 
after 7 days of treatment. 
In agreement with other studies [7-9], we failed to 
find any contamination in samples analyzed 
immediately after preparation of the serum eye-drops 
or during the follow-up of samples kept in the 
refrigerator at 4°C for 1-5 days. The results of our 
second experiment on repeated AS instillations and 
culturing at 2-hour intervals confirm that 
contamination rarely occurs during the handling and 
storage of serum eye-drops, if they are done correctly. 
Time of use and incorrect container handling by 
patients or personnel responsible for AS 
administration are the main factors involved in 
microbial contamination of AS [7-9]. If contamination 
of correctly used AS eye-drops is uncommon [7-9], 
infectious complications related to AS use are even 
rarer [1], probably because in most cases the 
antimicrobial agents contained in the serum, along 
with the concomitant use of topical antibiotics, could 
overcome an infection in its initial phase and prevent 
the development of true conjunctivitis and/or keratitis. 
 
Conclusion 
The results of this study suggest that, under the 
protocol described, preparation and storage of 
undiluted AS in insulin syringes is inexpensive, fast, 
and microbiologically safe, at least for the first five 
days after preparation and for a maximum of six 
instillations a day. Thus, this protocol may be of great 
importance in low-income countries, where ocular 
surface disorders needing treatment with AS are 
common. Even though, in the clinical setting, repeated 
use of eye-drops from the same container may increase 
the risk of bacterial and fungal contamination, this risk 
is expected to be minimal, if the container is stored in 
a refrigerator at 4°C between applications, handled 
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